Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advances in antibody-drug conjugates in cancer: latest updates from the 2026 AACR annual meeting.

Experimental hematology & oncology·2026
Same author

Rejuvenated Hematopoietic Stem and Progenitor Cell-Engineered CAR-Armored Natural Killer T Cells for Malignant Pleural Mesothelioma.

Research (Washington, D.C.)·2026
Same author

The Influence of Social Relationships on Third-Party Punishment: The Roles of Relationship Type Congruence and Threat Perception.

Behavioral sciences (Basel, Switzerland)·2026
Same author

Creatine uptake promotes dendritic cell activation and enhances antitumor immunity.

iScience·2026
Same author

Universal Nanovial Screening Enables Functional Discovery of Metabolite-Reactive T-Cell Receptors for Cancer Therapy.

ACS nano·2026
Same author

Synergizing hypomethylating agents with off-the-shelf CD70-targeted chimeric antigen receptor-engineered natural killer T cells for the treatment of acute myeloid leukemia.

Leukemia·2026

Related Experiment Video

Updated: Feb 26, 2026

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy
07:33

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Published on: September 19, 2025

889

In vivo CAR engineering for immunotherapy.

Yan-Ruide Li1,2, Yichen Zhu1,2, Tyler Halladay1,2

  • 1Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA, USA.

Nature Reviews. Immunology
|May 16, 2025
PubMed
Summary

In vivo chimeric antigen receptor (CAR) engineering offers a promising alternative to traditional ex vivo CAR therapy for cancer treatment. This approach streamlines production, reduces costs, and simplifies logistics for broader application.

More Related Videos

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
08:04

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

12.7K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.1K

Related Experiment Videos

Last Updated: Feb 26, 2026

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy
07:33

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Published on: September 19, 2025

889
In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
08:04

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

12.7K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.1K

Area of Science:

  • Immunology
  • Biotechnology
  • Oncology

Background:

  • Chimeric antigen receptor (CAR)-engineered immune cell therapy is a significant advancement in cancer treatment.
  • Current ex vivo CAR manufacturing is complex, costly, and requires strict patient selection, limiting its widespread use.
  • In vivo CAR engineering presents a potential solution to these limitations.

Purpose of the Study:

  • To review current in vivo CAR engineering strategies.
  • To compare in vivo and ex vivo CAR engineering methods.
  • To discuss the challenges and future prospects of in vivo CAR engineering.

Main Methods:

  • Review of nanoparticle-based delivery systems.
  • Review of viral delivery systems.
  • Review of bioinstructive implantable scaffolds.

Main Results:

  • In vivo CAR engineering offers advantages like streamlined production, reduced costs, and simplified logistics.
  • Preclinical findings support its use in treating solid tumors and improving therapeutic persistence and safety.
  • Various delivery systems (nanoparticles, viral vectors, scaffolds) are being developed.

Conclusions:

  • In vivo CAR engineering is a promising off-the-shelf therapy with the potential to overcome limitations of ex vivo manufacturing.
  • Further development is needed to enhance efficacy, persistence, and safety, particularly for solid tumors.
  • This approach holds significant promise for the future of cancer immunotherapy.